Name: BPC-157
Brand: Research-Grade
Availability: InStock

Question 1

How is BPC-157 typically administered in studies?

Accepted Answer

Preclinical studies have used intraperitoneal, oral, and local or topical routes. Reviews from the main research group report that BPC-157 was effective in gastrointestinal injury models given intraperitoneally, by mouth, or locally, and a rat alkali-burn study applied it topically. These are animal protocols; no human dose or route has been established in controlled trials.

Question 2

What is the evidence level for BPC-157 in humans?

Accepted Answer

Preliminary. The bulk of the literature is rodent and in-vitro work. Early clinical work under the code PL 14736 was described as safe in inflammatory bowel disease, and a 2025 review identified only three small human pilot studies (knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics). Large controlled trials are lacking.

Question 3

Is BPC-157 stable once reconstituted?

Accepted Answer

There is no published stability study for reconstituted research-grade BPC-157 vials, so any 'use within X days' figure is a vendor convention rather than measured data. Research peptides are generally kept refrigerated after reconstitution and protected from repeated temperature changes.

Question 4

Can BPC-157 be taken orally?

Accepted Answer

BPC-157 is reported to be stable in human gastric juice, which is unusual for a peptide. In animal studies it has been given by mouth for gastrointestinal targets, and the same regimens have been reported to improve tendon, ligament and bone healing in rodents. Whether oral BPC-157 is absorbed or effective in humans has not been established; in rats and dogs, intramuscular bioavailability was low to moderate and the peptide was rapidly broken down into small fragments.

Question 5

Is BPC-157 safe to combine with other peptides?

Accepted Answer

No controlled study has tested BPC-157 in combination with TB-500, GHK-Cu, or other peptides, so there is no evidence on interactions or on whether combinations add benefit. Stability of mixed solutions has not been studied either.

Question 6

What are the known side effects of BPC-157?

Accepted Answer

Reviews from the research group that developed BPC-157 report no toxicity in their animal work, and a 2025 review noted that the three small human pilot studies reported no adverse effects. However, there are no large human safety trials, so rare or long-term side effects cannot be ruled out, and products sold outside regulated channels carry their own quality and contamination risks.

Question 7

Does BPC-157 promote tumor growth or affect cancer risk?

Accepted Answer

BPC-157 promotes angiogenesis (new blood vessel formation) in preclinical models, associated with VEGFR2 activation, which raises a theoretical concern about supporting blood supply to existing tumors. This has not been tested adequately in humans. Individuals with active malignancies or a history of cancer should be particularly cautious and speak with an oncologist before considering any angiogenic peptide.

Question 8

Is BPC-157 banned by WADA or sports anti-doping agencies?

Accepted Answer

Anti-doping status is set by the World Anti-Doping Agency's Prohibited List, which is revised every year and also covers unapproved investigational substances. Athletes subject to drug testing should check the current list and their sport's rules before using BPC-157 or any other unapproved peptide.

Question 9

How does BPC-157 differ from TB-500 for injury recovery?

Accepted Answer

Both are studied for tissue repair but through different proposed mechanisms: BPC-157 has been linked in cell and animal studies to growth-hormone receptor up-regulation, nitric-oxide signaling, and VEGFR2-driven angiogenesis, while thymosin β4 (the protein TB-500 is derived from) is an actin-binding protein studied for cell migration and wound and cardiac repair. BPC-157's preclinical record is strongest in gastrointestinal and tendon models. No controlled human trial has compared them or tested them together.

Question 10

Can BPC-157 be used alongside GLP-1 medications to offset their gastrointestinal side effects?

Accepted Answer

This is a common community rationale — BPC-157's cytoprotective effects on the GI tract are proposed to ease the nausea and gut discomfort that GLP-1 agonists can cause. It is a theoretical, unproven pairing; no clinical trial has tested BPC-157 with GLP-1 drugs, and slowed gastric emptying from GLP-1 therapy complicates any assumptions about absorption. GI side effects of GLP-1 medications are usually managed with dose titration and dietary adjustments under clinical guidance.

Question 11

How does BPC-157 differ from its stabilized variants like pegylated BPC-157 or arginate salt forms?

Accepted Answer

Standard BPC-157 is cleared quickly — its elimination half-life in rats and dogs was under 30 minutes — so modified forms have appeared, including pegylated BPC-157 and arginate or acetate salt forms marketed for stability or solubility. We found no published human data on these variants, so claims of superiority are theoretical. All remain research-only compounds.

Question 12

Why is there so little human clinical trial data on BPC-157?

Accepted Answer

BPC-157 has not followed a full regulatory development path, and most of the existing literature comes from a relatively concentrated group of academic researchers working in animal models. That work is valuable for mechanism but does not substitute for randomized human trials with defined endpoints. The result is a striking mismatch: a broad preclinical record alongside almost no rigorous human efficacy data. That gap is the most important caveat when interpreting any claim about BPC-157, and it is why it remains a research compound rather than an approved therapy.

Question 13

Does the route of administration change what BPC-157 can plausibly do?

Accepted Answer

In animal studies BPC-157 has been given by mouth, by intraperitoneal injection, and locally or topically, and it is reported to be stable in gastric juice. Pharmacokinetic work in rats and dogs found rapid clearance and partial bioavailability after intramuscular injection. No controlled human study has compared routes, so the ideal route, dose, and whether local injection outperforms systemic delivery in people are unknown.

Origin / Manufacturer	Synthetic
Active Components	BPC-157 pentadecapeptideBacteriostatic water (for reconstitution)
Storage	Lyophilized: room temperature. Reconstituted: 2–8°C
Shelf Life	Lyophilized 24+ months; reconstituted 30 days refrigerated
Form Factor	Lyophilized powder (5 mg or 10 mg vial)

BPC-157

Specifications

Frequently Asked Questions

Sources & References

Related Peptides

CJC-1295 + Ipamorelin

GHK-Cu (Copper Tripeptide-1)

TB-500 (Thymosin β4 Fragment)